The Food and Drug Administration May 8 expanded the list of drugs covered under newly flexible compounding policies to include two that may be in short supply because of the COVID-19 pandemic: morphine sulfate and epinephrine.

Under the temporary policy, which is to remain in effect for no longer than the duration of the COVID-19 public health emergency, FDA said it does not intend to take action against pharmacies for compounding drug products that are essentially copies of commercially available drugs or for providing drugs to hospitals without first obtaining patient-specific prescriptions, as long as certain circumstances outlined in the guidance are present and other conditions established in section 503A of the Federal Food, Drug, and Cosmetic Act are met.

Related News Articles

Headline
The AABB, America’s Blood Centers and the American Red Cross Friday urged eligible individuals to donate blood, calling the nation’s blood supply “critically…
Headline
A new analysis by Global Health 50/50, an initiative to advance gender equality in global health, sheds light on sex disparities in COVID-19 deaths.…
Headline
The Department of Health and Human Services Friday announced the new option of saliva tests at federal community-based testing sites in areas experiencing…
Headline
Jim Skogsbergh, president and CEO of Advocate Aurora Health, will join AHA Board Chair Melinda Estes, M.D., Oct. 22 at 3:30 p.m. ET to discuss COVID-19’s…
Chairperson's File
COVID-19 is a pandemic with no precedent, and certainly no equal. In many ways, we’ve been learning as we go. For health care professionals, this has elevated…
Headline
A recent article on hospital field finances ignores the diverse experiences of hospitals during the pandemic, particularly those under significant financial…